At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 580 enrolled
Drug / intervention
Mavacamten +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
In Brief
A Phase 3 clinical trial evaluating Mavacamten and Placebo for Cardiomyopathy, Hypertrophic. Completed, enrolled 580 participants across 224 sites in 23 countries.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiomyopathy, Hypertrophic
CountriesAustralia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Hungary, India, Israel, Italy, Japan, Netherlands, Norway, Poland, Portugal, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartDec 2022
Primary CompletionMar 2025
Study CompletionOct 2025
TodayJul 2026
First PostedOct 17, 2022
Enrollment StartDec 14, 2022
Primary CompletionMar 6, 2025
Study CompletionOct 20, 2025
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 3.7 years ago
Interventions
Mavacamtendrug
Specified dose on specified days
Placeboother
Specified dose on specified days